Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$417.86 USD

417.86
1,845,879

+3.85 (0.93%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $417.84 -0.02 (0.00%) 4:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y

by Zacks Equity Research

Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.

Cigna (CI) & Oscar Health Boost Presence in Philadelphia

by Zacks Equity Research

Cigna (CI) & Oscar Health's plans are likely to target businesses with 1-50 employees.

UnitedHealth (UNH) Unit Adds Features to Surest Plans

by Zacks Equity Research

UnitedHealth Group's (UNH) arm UnitedHealthcare advances Surest plans by including features to lure more employers into opting for the attractive package and bolster its geographic reach.

Are Medical Stocks Lagging Alkermes (ALKS) This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.

Ensign Group (ENSG) Stock Up 6% Since Q2 Earnings Release

by Zacks Equity Research

Ensign Group's (ENSG) second-quarter results reflect revenue growth, and solid contributions from the Skilled Services and Standard Bearer segments. A hiked 2022 EPS guidance bodes well.

Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss

by Zacks Equity Research

Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Community Health (CYH) Down 30.3% Since Q2 Earnings Report

by Zacks Equity Research

Community Health (CYH) expects capex to remain within $400-$450 million in 2022.

Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.

Humana (HUM) Q2 Earnings Beat Estimates, Ups '22 EPS View

by Zacks Equity Research

Humana's (HUM) second-quarter earnings benefit from higher premiums and strong individual Medicare Advantage membership growth. A hiked adjusted EPS guidance for 2022 is noteworthy.

3 Reasons Why Elevance Health (ELV) Is a Great Growth Stock

by Zacks Equity Research

Elevance Health (ELV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ELV vs. GDRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Universal Health (UHS) Q2 Earnings Beat on Strong Segments

by Zacks Equity Research

Universal Health's (UHS) second-quarter results benefit from strong contributions from Acute Care Hospital Services and Behavioral Health Care Services segments, partly offset by elevated operating costs.

Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.

Tenet Healthcare (THC) Q2 Earnings Beat, Trims '22 EPS View

by Zacks Equity Research

Tenet Healthcare's (THC) second-quarter earnings benefit from strong Ambulatory Care and Conifer segments. However, a trimmed EPS view for 2022 might raise concerns for investors.

HCA Healthcare (HCA) Q2 Earnings Beat on Better Patient Volumes

by Zacks Equity Research

HCA Healthcare's (HCA) second-quarter results reflect improved revenues stemming from better same-facility emergency room visits. However, the results were partly offset by elevated salaries and benefits cost.

Elevance Health (ELV) Q2 Earnings Beat on Higher Premiums

by Zacks Equity Research

Elevance Health (ELV) hikes adjusted net income estimate for this year to more than $28.70 per share.

Anthem (ELV) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Anthem (ELV) delivered earnings and revenue surprises of 4.15% and 0.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.

Anthem (ELV) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Anthem (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?

by Zacks Equity Research

UnitedHealth Group's (UNH) second-quarter results are likely to reflect improving premiums, products and higher expenses.

Why You Should Hold Elevance Health (ELV) in Your Portfolio

by Zacks Equity Research

Elevance Health (ELV) continues witnessing a rise in the usage of its virtual care services, which is a vital driver.